Novo Nordisk’s Sogroya is now approved for children aged 2.5 or older with idiopathic short stature, small for gestational age, and Noonan Syndrome.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-okays-new-indications-once-weekly-growth-hormone-2026a10006dl?src=rss
Author :
Publish date : 2026-03-02 11:06:00
Copyright for syndicated content belongs to the linked Source.